Standigm and Korea institute of science and technology (KIST) announced a research collaboration to develop a new small molecule medicine for Autism. The drug candidates chosen by Standigm’s AI drug discovery technology will validate experimentally by using KIST’s animal models.
CrystalGenomics, Inc., Standigm’s partner company, today announced a drug predicted by Standigm’s artificial intelligence technology showed the evidence that it may reuse for cancer treatment. The drug is an FDA-proved drug for other therapeutic uses. It has been only three months to sign the partnership between Standigm, Inc. and CrystalGenomics, Inc.